Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Amato

Showing results (41-50 of 287) with videos related to

Pageof 29
Sort By:
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|April 18, 2015
European men who have sex with men still at risk of HIV infection despite three decades of prevention effortsK Haar, A J Amato-Gauci
Biochemistry|June 27, 2017
Cytotoxic and Mutagenic Properties of C3'-Epimeric Lesions of 2'-Deoxyribonucleosides in Escherichia coli CellsPengcheng Wang, Nicholas J Amato, Yinsheng Wang
Chembiochem : a European Journal of Chemical Biology|January 3, 2013
The impact of structure on oxidatively generated DNA damage products resulting from the C3'-thymidinyl radicalNicholas J Amato, Amanda C Bryant-Friedrich
Investigational New Drugs|November 27, 2002
Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancerRobert J Amato, Cherie Perez, Lance Pagliaro
American Journal of Clinical Oncology|June 6, 2008
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinomaRobert J Amato, Rahul Malya, Anish Rawat
Cancer|February 14, 2006
Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinomaRobert J Amato, Margaret Morgan, Anish Rawat
Cancer Investigation|February 14, 2013
Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatmentsRobert J Amato, Somyata Saxena, Mika Stepankiw
American Journal of Clinical Oncology|December 9, 2008
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancerRobert J Amato, Joan Hernandez-McClain, Haby Henary
Journal of Pediatric Surgery|October 1, 1977
A "second" radial artery for monitoring the perioperative pediatric cardiac patientJ J Amato, E Solod, R J Cleveland
Clinical Genitourinary Cancer|October 1, 2008
Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study resultsRobert J Amato, Jaroslaw Jac, Joan Hernandez-McClain
Pageof 29

Showing results (41-50 of 287) with videos related to

Sort By:
Pageof 29
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|April 18, 2015
European men who have sex with men still at risk of HIV infection despite three decades of prevention effortsK Haar, A J Amato-Gauci
Biochemistry|June 27, 2017
Cytotoxic and Mutagenic Properties of C3'-Epimeric Lesions of 2'-Deoxyribonucleosides in Escherichia coli CellsPengcheng Wang, Nicholas J Amato, Yinsheng Wang
Chembiochem : a European Journal of Chemical Biology|January 3, 2013
The impact of structure on oxidatively generated DNA damage products resulting from the C3'-thymidinyl radicalNicholas J Amato, Amanda C Bryant-Friedrich
Investigational New Drugs|November 27, 2002
Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancerRobert J Amato, Cherie Perez, Lance Pagliaro
American Journal of Clinical Oncology|June 6, 2008
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinomaRobert J Amato, Rahul Malya, Anish Rawat
Cancer|February 14, 2006
Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinomaRobert J Amato, Margaret Morgan, Anish Rawat
Cancer Investigation|February 14, 2013
Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatmentsRobert J Amato, Somyata Saxena, Mika Stepankiw
American Journal of Clinical Oncology|December 9, 2008
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancerRobert J Amato, Joan Hernandez-McClain, Haby Henary
Journal of Pediatric Surgery|October 1, 1977
A "second" radial artery for monitoring the perioperative pediatric cardiac patientJ J Amato, E Solod, R J Cleveland
Clinical Genitourinary Cancer|October 1, 2008
Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study resultsRobert J Amato, Jaroslaw Jac, Joan Hernandez-McClain
Pageof 29